+1 700 888 1234
Effingerstrasse 40 3008 Bern Switzerland
Bristol Myers Squibb has released a new Press Release announcing that the European Medicines Agency (EMA) has validated the marketing authorization application for repotrectinib. Repotrectinib […]
consectetur adipisicing elit, sed do eiusmod tempor incididunt laboret dolore magna aliqua. Ut enim minim veniam quis nostrud exercitation ullamco laboris.
Website Under Construction
We are currently rebuilding our website, and look forward to its launch later in 2026.
Until then, this website is not being updated. Feel free to continue browsing, or visit our news site for the latest updates.
